Objective. To describe the history of SSc-associated pulmonary arterial hypertension (SSc-PAH) in patients with New York Heart Association (NYHA) functional class (FC) II dyspnoea at diagnosis.
Introduction
Breathlessness is a common symptom in patients with SSc-associated pulmonary arterial hypertension (SSc-PAH). A majority of patients with SSc-PAH are in New York Heart Association (NYHA) functional class (FC) III or IV at diagnosis [1, 2] . Recent data indicate that patients with severe disease in NYHA FCs III or IV exhibit poorer survival as compared with patients with mildly symptomatic disease in NYHA FC II [3] [4] [5] . Until recently, little data have been published on the history and outcomes of patients with SSc-PAH who were in NYHA FC II at diagnosis. In this study, we present the functional and haemodynamic characteristics, evolution and 5-year survival observed among patients with SSc-PAH in NYHA FC II at PAH diagnosis from three expert reference centres in France.
Patients were classified as having SSc according to Masi et al. [6] and lcSSc or dcSSc according to LeRoy et al. [7] . All consecutive SSc patients diagnosed with PAH from January 2000 were retrospectively included in the study.
Patients with other causes of pulmonary hypertension (PH) were excluded (particularly patients with severe interstitial lung disease based on pulmonary functional tests and high-resolution CT scan, or those with postcapillary PH). Diagnosis of PAH was confirmed using right heart catheterization (RHC), and defined as mean pulmonary arterial pressure (mPAP) 525 mmHg at rest with a mean pulmonary arterial wedge pressure (mPAWP) 415 mmHg. In patients with mild mPAP increase (<35 mmHg) and normal mPAWP at rest, a loading test was done during RHC to exclude post-capillary PH due to left ventricular diastolic dysfunction, which is at least as frequent as PAH in patients with SSc [8] .
Evaluation of dyspnoea was based on NYHA FC, as previously described [9] . NYHA FC was defined by the senior cardiologist or pneumologist at the time of the RHC. History and characteristics of patients at PAH diagnosis, including 6-min walk distance (6MWD), Doppler echocardiography and pulmonary function test results and haemodynamic parameters, were described according to NYHA FC. Survival data were right-censored at 5 years and survival was estimated using the KaplanMeier method. Comparisons of survival curves were conducted using the log-rank test. Analysis of variance (ANOVA) was used for comparisons of continuous variables and 2 testing for comparisons of categorical variables. Results of ANOVA were confirmed by non-parametric tests (Kruskall-Wallis' test). As the non-parametric tests gave results that were consistent with those from ANOVA, only ANOVA results are presented here. This study was approved by the French 'Informatique et Liberté s' institution in accordance with the current French legislation.
Results
Data from 77 consecutive patients with SSc-PAH were obtained from Bé clè re Hospital, Clamart (n = 43), Huriez Hospital, Lille (n = 23) and Cochin Hospital, Paris (n = 11). As RHC (the recognized gold standard for PAH diagnosis) was used, all cases of post-capillary PH were excluded from the study. Twelve patients (15.6%) presented in NYHA FC II at PAH diagnosis. Clinical and haemodynamic data, stratified according to NYHA FC, are presented in Table 1 . No difference was seen between centres (data not shown).
Patients in NYHA FC II were typically younger, with less severe haemodynamic parameters than patients in FCs III and IV; however, their duration of SSc prior to PAH diagnosis was comparable. The diffusing capacity for carbon monoxide (DL CO ) was less impaired in patients in NYHA FC II, although these differences were not significant. No differences were observed between immunological status and lung volumes were subnormal (data not shown). All haemodynamic parameters were significantly less impaired in patients in NYHA FC II, with lower pulmonary vascular resistance and higher cardiac index. The 6MWD was also significantly greater among patients in NYHA FC II, compared with the other patient subgroups.
Individual data at PAH diagnosis for the 12 patients in NYHA FC II are displayed in Table 2 . Six patients had an mPAP 430 mmHg, further suggesting mild PAH; however, six patients exhibited higher levels of mPAP, ranging from 38 to 60 mmHg. Moreover, 5 out of these 12 patients had a cardiac index <3 l/min/m 2 .
All patients were treated according to the current recommendations [9] at the time of diagnosis (Table 2) . After www.rheumatology.oxfordjournals.org a mean follow-up of 44 months, only four patients remained stable in NYHA FC II, while eight deteriorated to NYHA FCs III or IV. Three patients died during follow-up. One death was due to rectal cancer, not worsening PAH, and therefore the patient was receiving appropriate first-line treatment (bosentan monotherapy) at death. Another patient died immediately after surgery for acute cholecystitis, as a result of cardiac failure due to worsening of previously stable PAH. The third death was also due to worsening PAH; unfortunately this patient refused further re-evaluations at the PAH expert centre. All three patients had severely impaired haemodynamic parameters, with high pulmonary vascular resistance (>800 dyn/s/cm 5 /m 2 ). Survival among patients in NYHA FC II was 100, 91 and 80% at 1, 2 and 3 years, respectively. Three-year survival was significantly better (P = 0.006) among patients in NYHA FC II (80%) vs those in NYHA FCs III (72%) and IV (30%) (Fig. 1) .
Discussion
In this retrospective review of data from 77 patients with SSc-PAH, we observed that 12 patients (15.6%) were mildly symptomatic at the time of PAH diagnosis (NYHA FC II). Overall, mean haemodynamic parameters were less impaired among these patients vs those in FCs III and IV. Nevertheless, six patients in NYHA FC II exhibited mPAP >35 mmHg and five patients exhibited a cardiac index <3 l/min/m 2 , confirming that mildly symptomatic patients with SSc-PAH frequently exhibit severe haemodynamic compromises at diagnosis. Clinical worsening (defined as deterioration in NYHA FC) was observed in approximately two-thirds of SSc-PAH patients in NYHA FC II in our cohort, after a mean follow-up of almost 4 years. This observation is comparable with the rate of disease progression of 39% observed among SSc-PAH patients in FC II in the UK PH service [4] . Three-year survival of patients with SSc-PAH in NYHA FC II was 80% in this study, compared with 65% in patients from the UK PH service [4] . This high 3-year mortality rate questions the supposedly good prognosis of patients with mildly symptomatic disease.
It should be noted that all patients in this study were treated in accordance with current guidelines, emphasizing that patients with PAH-SSc continue to exhibit a poor outcome, even in the modern management era. In a recent trial of the dual endothelin receptor antagonist bosentan in patients with mildly symptomatic (NYHA FC II) PAH, placebo-treated subjects experienced significantly greater disease progression at 6 months vs bosentan-treated subjects. In this trial, 13% of placebo-treated patients initially in FC II worsened to Class III or IV at 6 months, and this was further supported by better haemodynamic outcomes being observed in treated patients, as compared with placebo [10] .
Mildly symptomatic SSc-PAH in NYHA FC II is relatively rare, representing <25% of patients in most published registries [2, 3] . This proportion of patients could, however, increase in future due to the introduction of screening for PAH among this high-risk population, as advocated by clinical practice guidelines [11] . In two different screening programmes, SSc-PAH patients in NYHA FCs I and II represented 50 and 71%, respectively, of newly diagnosed patients [12, 13] . As in our study, the reported duration from SSc onset to PAH diagnosis did not differ between patients in NYHA FC II vs those in FCs III and IV. We, therefore, consider that the better clinical and haemodynamic presentation in patients in NYHA FC II is not only due to a lead time bias. Whether better management of mildly symptomatic patients in NYHA FC II will translate into better survival in future remains to be firmly demonstrated. However, the significant clinical and haemodynamic effects of targeted therapies, such as bosentan, in patients with PAH in FC II [10] , suggests that these patients may benefit from PAH specific treatment.
A possible limitation of this study is that some patients categorized in NYHA FC II at diagnosis may have underestimated their degree of dyspnoea, due to a subconscious adaption of their daily activities to their capabilities. Such an occurrence may have led to an inappropriate classification into a lower FC.
In conclusion, patients with mildly symptomatic SSc-PAH in NYHA FC II frequently present with significant marked haemodynamic compromise and poor prognosis. We observed within a 5-year period that approximately two-thirds of such patients can deteriorate to NYHA FCs III or IV and some will die, which suggests that more aggressive management may be of benefit to this patient population. Further studies are needed, however, to determine predictors of outcome in these patients. These results highlight the importance of a systematic screening strategy for SSc-PAH, even among patients who are mildly symptomatic.
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